Imagen de Portada

Equal Marginal Power for Co-Primary Endpoints

Fuente: arXiv

Guardado en:

Detalles Bibliográficos
Autor principal:	Bond, Simon
Formato:	Preprint
Publicado:	2026
Materias:	Methodology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The FORSS Framework for Sample Size and Power Calculations With Win Statistics for Hierarchical Endpoints
por: Zhang, Baoshan, et al.
Publicado: (2026)

Improving Power in Randomized Controlled Trials with Time-to-Event Endpoints: A Risk-Free Approach
por: Zhou, Junyi, et al.
Publicado: (2026)

Marginal Analysis of Count Time Series in the Presence of Missing Observations
por: Nik, Simon
Publicado: (2024)

Power and Sample Size Calculations for Bayes Factors in two-arm clinical Phase II Trials with binary Endpoints
por: Kelter, Riko
Publicado: (2026)

On Cluster Randomized Trials with the Desirability of Outcome Ranking (DOOR) Endpoints
por: Shao, Wanying, et al.
Publicado: (2026)

A Surrogate Endpoint Based Provisional Approval Causal Roadmap
por: Gilbert, Peter B., et al.
Publicado: (2024)

Testing Prioritized Composite Endpoint with Multiple Follow-up Time Examinations
por: Mou, Yunhan, et al.
Publicado: (2025)

Evaluation of Surrogate Endpoints Based on Meta-Analysis with Surrogate Indices
por: Stijven, Florian, et al.
Publicado: (2025)

Prediction Intervals for Interim Events in Randomized Clinical Trials with Time-to-Event Endpoints
por: Ratti, Edoardo, et al.
Publicado: (2026)

Correlation Matters! Streamlining the Sample Size Procedure with Composite Time-to-event Endpoints
por: Mou, Yunhan, et al.
Publicado: (2025)

A Unified Approach to Covariate Adjustment for Survival Endpoints in Randomized Clinical Trials
por: Zhang, Zhiwei, et al.
Publicado: (2025)

Interpretational challenges of the Win Ratio in analyzing Hierarchical Composite Endpoints in Chronic Kidney Disease
por: Thomsen, Henrik F., et al.
Publicado: (2025)

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials
por: Maity, Arnab Kumar, et al.
Publicado: (2024)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
por: Long, James P., et al.
Publicado: (2025)

Marginal Interventional Effects
por: Zhou, Xiang, et al.
Publicado: (2022)

Utility-Based Dose Optimization Approaches for Multiple-Dose Randomized Trial Designs Accounting for Multiple Endpoints
por: DAngelo, Gina, et al.
Publicado: (2025)

On the Utility of Equal Batch Sizes for Inference in Stochastic Gradient Descent
por: Singh, Rahul, et al.
Publicado: (2023)

Tutorial for Surrogate Endpoint Validation Using Joint modeling and Mediation Analysis
por: Coent, Quentin Le, et al.
Publicado: (2025)

Tipping Point Sensitivity Analysis for Missing Data in Time-to-Event Endpoints: Model-Based and Ad hoc Approaches
por: Oodally, Ajmal, et al.
Publicado: (2025)

Nonparanormal Adjusted Marginal Inference
por: Dandl, Susanne, et al.
Publicado: (2025)

Toward Valid Generative Clinical Trial Data with Survival Endpoints
por: Chassat, Perrine, et al.
Publicado: (2025)

Estimation and Inference for Win Measures with Multiple Ordinal Endpoints Subject to Missingness
por: Liu, Yi, et al.
Publicado: (2026)

Diffeomorphic Cortical Alignment via Direct Warping of Streamline Endpoints
por: Xiang, Yang, et al.
Publicado: (2026)

Multi-Dimensional Composite Endpoint Analysis via the Choquet Integral: Block Recurrent Encoding and Comparative Advantage Mapping
por: Tanboga, Ibrahim Halil
Publicado: (2026)

Study Duration Prediction for Clinical Trials with Time-to-Event Endpoints Using Mixture Distributions Accounting for Heterogeneous Population
por: Zhang, Hong, et al.
Publicado: (2023)

Joint Estimation of Marginal and Heterogeneous Treatment Effects
por: Wuethrich, Leticia, et al.
Publicado: (2026)

Causal Discovery in Structural VAR Models Under Equal Noise Variance
por: HasanAbadi, SeyedSina Seyedi, et al.
Publicado: (2026)

Marginal Structural Modeling of Representative Treatment Trajectories
por: Liu, Jiewen, et al.
Publicado: (2024)

Randomization Inference When N Equals One
por: Liang, Tengyuan, et al.
Publicado: (2023)

Optimal sequential two-stage Bayes Factor Design for two-arm clinical Phase II Trials with binary Endpoints
por: Kelter, Riko
Publicado: (2026)

Marginal Causal Effect Estimation with Continuous Instrumental Variables
por: Dong, Mei, et al.
Publicado: (2025)

The Marginal Likelihood of two-way tables and Ecological Inference
por: Forcina, Antonio
Publicado: (2025)

Estimation and Inference of the Win Ratio for Two Hierarchical Endpoints Subject to Censoring and Missing Data
por: Liu, Yi, et al.
Publicado: (2026)

Marginal Effects for Probit and Tobit with Endogeneity
por: Evdokimov, Kirill S., et al.
Publicado: (2023)

A Reflection on the Impact of Misspecifying Unidentifiable Causal Inference Models in Surrogate Endpoint Evaluation
por: Deliorman, Gokce, et al.
Publicado: (2024)

A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization
por: Gu, Xuemin, et al.
Publicado: (2026)

Estimating Dynamic Marginal Policy Effects under Sequential Unconfoundedness
por: Lai, I-han, et al.
Publicado: (2026)

Marginal and conditional summary measures: transportability and compatibility across studies
por: Remiro-Azócar, Antonio, et al.
Publicado: (2025)

Exact Simulation of Longitudinal Data from Marginal Structural Models
por: Lin, Xi, et al.
Publicado: (2025)

Estimating the Joint Distribution of Two Binary Variables with Marginal Statistics
por: Shang, Longwen, et al.
Publicado: (2025)